FDA & Government News

​​​​​​​PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.

Share

The FDA has approved deucravacitinib (Sotyktu), the first tyrosine kinase 2 (TYK2) inhibitor for adults with active psoriatic arthritis (PsA). This once-daily oral treatment demonstrated significant improvements in disease activity compared to placebo in two phase 3 trials: POETYK PsA-1 and POETYK PsA-2. Both studies showed that deucravacitinib achieved ACR20 responses in 54% of participants, with additional endpoints also favoring the treatment. The drug selectively targets TYK2 signaling pathways, leading to modulation of inflammatory responses in PsA.

Original Source(s)

​​​​​​​PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.

  • by Kathryn Wighton

  • March 9, 2026

  • 3 min

Related Content

Upadacitinib and Pain in RA, PsA

Mediation analysis suggests direct and indirect effects on pain reduction in rheumatoid and psoriatic arthritis.

PsA Clusters Identified for Tailored Treatment: Longitudinal Study

Discovery of Novel Susceptibility Gene May Shed Light on Etiology of Psoriatic Arthritis Mutilans

Researchers may have uncovered genetic mechanisms underlying psoriatic arthritis mutilans.